Form 4: Elanco Director Lawrence Kurzius Deferrs Fees into Stock Units
SEC Form 4 Filing
Director Lawrence Kurzius elected to defer director fees into Elanco Animal Health Inc. stock units.
Summary
- On June 28, 2024, Lawrence Erik Kurzius, a director of Elanco Animal Health Inc., elected to defer director cash retainer fees into the company's Deferred Stock Account.
- This deferral resulted in the acquisition of 2,673.0028 Deferred Stock Units, each equivalent to one share of Elanco common stock.
- The price per share on the grant date was $14.43.
- Following the transaction, Mr. Kurzius beneficially owns 29,528.1471 Deferred Stock Units directly.
- These units will be settled in stock after his separation of service from the Company's Board of Directors.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The director is taking compensation in stock, which aligns interests with shareholders. It's a routine transaction, but indicates confidence.
Positives
- Director's decision to take compensation in stock aligns his interests with shareholders.
- The deferral plan allows for long-term investment in the company's success.
Future Outlook
The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
Industry Context
Director compensation in the form of stock units is a common practice to align management interests with shareholder value in the animal health industry.
Comparison to Industry Standards
- Many companies in the animal health sector, such as Zoetis and IDEXX Laboratories, offer stock-based compensation to their directors and executives.
- These plans often include deferred stock units or restricted stock awards that vest over time, encouraging long-term commitment and performance.
- The specific terms of these plans, such as vesting schedules and settlement dates, can vary widely based on company policies and individual agreements.
Stakeholder Impact
- Shareholders may view the director's decision to take compensation in stock as a positive sign, aligning his interests with theirs.
- The deferral plan does not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| May 14, 2024 | Date of Power of Attorney execution, authorizing individuals to act on behalf of Lawrence Kurzius for SEC filings. |
| June 28, 2024 | Date of transaction: Lawrence Kurzius acquired 2,673.0028 Deferred Stock Units. |
| July 02, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.